The Chinese Biopharmaceutical Association-USA (CBA) recently hosted the China Pharmaceutical Enterprise Association (CPEA) during it’s annual conference.
The event marked a milestone for both groups, who have experienced substantial growth recently. Twenty years ago, CBA was a tiny group of young scientists, all with ties to China. However, this small group had a large vision: to create a platform for collaboration in life sciences and the biopharmaceutical industry. That vision was put into action and today, CBA has grown into a truly global organization with a strong and growing reputation. While remaining true to their founding mission, their annual conference serves to reinforce and extend the commitment of CBA to foster greater global collaboration and new partnerships between China and USA in the biotech and pharmaceutical arenas.
Likewise, CPEA’s key function is also to provide services. Their member companies are advised on four key areas:
During CPEA’s time in the United States, the group also met with China BioVentures (“CBV”), an organization focused on the acquisition of medical technologies from Europe and the United States. CBV operates primarily by forming companies and selling a majority control to leading Chinese companies, eliminating the challenges for both Chinese and American firms. CPEA had the opportunity to listen to CBV’s business strategy and catalogue of healthcare companies. In turn, CBV used the meeting as an opportunity to learn more about the CPEA delegates’ interests and begin to develop a long-term relationship.
CBV’s mission is to provide services as an alternative to the language, cultural and trust issues that make cross border transactions inefficient, costly and risky. Their long-standing relationships with senior healthcare executives and investors allow for efficient communications, fair transactions and ongoing guidance.
Through the convergence of a technology partner, development partner and operating partner, CBV is able to offer a free-standing entity in a structure that is efficient and flexible.
The meetings between the parties were critical in the ongoing importance of China-U.S. collaboration, in addition to the critical need for innovation healthcare solutions.